Muscular dystrophy clue

Patients with Duchenne muscular dystrophy (DMD) have a genetic mutation that causes incurable muscle degeneration. Research has shown that the immune system plays a complex, double-sided role in muscular dystrophy—promoting both muscle repair and muscle degradation.

In their recent article in Frontiers in Pharmacology, Jonathan H. Soslow, MD, MSCI, Sergey Ryzhov, MD, Ph.D., and colleagues studied blood samples from normal people and people with DMD, and found that the patients with DMD had more T cells expressing a surface protein called CD26 compared to normal patients.

Additionally, in the DMD patients, the level of CD26-expressing T cells correlated with increased . This may be because CD26 can bind an enzyme called adenosine deaminase (ADA), which can increase the levels of inosine, an anti-inflammatory molecule, in muscle.

The researchers hypothesize that the increased CD26-expressing cells help slow down muscle degradation in DMD patients by bringing more ADA into muscles. Their work shines a light on potential new therapeutic targets for DMD patients.

Explore further

New target may slow disease progression in Duchenne muscular dystrophy

More information: Jonathan H. Soslow et al. Increased Number of Circulating CD8/CD26 T Cells in the Blood of Duchenne Muscular Dystrophy Patients Is Associated with Augmented Binding of Adenosine Deaminase and Higher Muscular Strength Scores, Frontiers in Pharmacology (2017). DOI: 10.3389/fphar.2017.00914
Citation: Muscular dystrophy clue (2018, February 12) retrieved 3 June 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments